Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 45.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 80,405 shares of the company's stock after purchasing an additional 25,160 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.07% of Revolution Medicines worth $2,306,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of RVMD. Point72 Hong Kong Ltd acquired a new position in Revolution Medicines during the 2nd quarter worth approximately $39,000. US Bancorp DE boosted its position in Revolution Medicines by 68.1% during the 2nd quarter. US Bancorp DE now owns 1,575 shares of the company's stock worth $42,000 after acquiring an additional 638 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Revolution Medicines by 76.5% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,418 shares of the company's stock valued at $74,000 after buying an additional 1,481 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Revolution Medicines by 101.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,802 shares of the company's stock valued at $78,000 after buying an additional 1,409 shares during the last quarter. Finally, Fred Alger Management LLC acquired a new stake in shares of Revolution Medicines in the 3rd quarter valued at approximately $126,000. 94.34% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Stephen Michael Kelsey sold 2,123 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $31.58, for a total value of $67,044.34. Following the transaction, the insider now directly owns 270,909 shares of the company's stock, valued at $8,555,306.22. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Stephen Michael Kelsey sold 2,123 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $31.58, for a total value of $67,044.34. Following the transaction, the insider now directly owns 270,909 shares of the company's stock, valued at $8,555,306.22. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mark A. Goldsmith sold 7,500 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $35.48, for a total value of $266,100.00. Following the completion of the sale, the insider now owns 452,879 shares of the company's stock, valued at $16,068,146.92. The disclosure for this sale can be found here. Insiders have sold a total of 20,205 shares of company stock valued at $671,249 over the last ninety days. 8.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

RVMD has been the subject of several research reports. Raymond James raised Revolution Medicines from an "outperform" rating to a "strong-buy" rating and raised their price target for the company from $36.00 to $48.00 in a report on Wednesday, April 10th. Wedbush raised their price target on Revolution Medicines from $41.00 to $42.00 and gave the company an "outperform" rating in a report on Tuesday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price target (up previously from $36.00) on shares of Revolution Medicines in a report on Monday, April 8th. Bank of America raised Revolution Medicines from a "neutral" rating to a "buy" rating and raised their price target for the company from $31.00 to $34.00 in a report on Friday, January 5th. Finally, Oppenheimer increased their price objective on Revolution Medicines from $43.00 to $45.00 and gave the stock an "outperform" rating in a research report on Friday, April 12th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $41.20.

Revolution Medicines Trading Down 2.5 %

Revolution Medicines stock traded down $0.91 during midday trading on Friday, reaching $34.92. The company's stock had a trading volume of 1,243,721 shares, compared to its average volume of 1,386,870. Revolution Medicines, Inc. has a 52 week low of $15.44 and a 52 week high of $38.73. The business has a 50-day moving average price of $31.70 and a 200-day moving average price of $27.59. The stock has a market cap of $5.75 billion, a PE ratio of -9.26 and a beta of 1.54.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.29). The firm had revenue of $0.74 million during the quarter, compared to analysts' expectations of $1.20 million. During the same quarter last year, the firm earned ($0.63) earnings per share. The company's quarterly revenue was down 95.2% on a year-over-year basis. As a group, research analysts predict that Revolution Medicines, Inc. will post -3.18 EPS for the current fiscal year.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.